PTC
RPRX icon

Philadelphia Trust Company’s Royalty Pharma RPRX Stock Holding History

Philadelphia Trust Company’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-58,095
Closed -$1.79M – 232
2023
Q2 		$1.79M Sell
58,095
-155,335
-73% -$5.26M 0.17% 94
2023
Q1 		$7.69M Sell
213,430
-6,510
-3% -$241K 0.78% 34
2022
Q4 		$8.69M Sell
219,940
-8,310
-4% -$347K 0.93% 26
2022
Q3 		$9.17M Sell
228,250
-3,295
-1% -$141K 1.04% 25
2022
Q2 		$9.73M Buy
231,545
+1,860
+0.8% +$76.2K 1% 27
2022
Q1 		$8.95M Buy
229,685
+1,750
+0.8% +$68.7K 0.71% 39
2021
Q4 		$9.08M Sell
227,935
-3,370
-1% -$131K 0.66% 45
2021
Q3 		$8.36M Buy
231,305
+58,280
+34% +$2.26M 0.62% 48
2021
Q2 		$7.09M Buy
173,025
+550
+0.3% +$23.4K 0.49% 54
2021
Q1 		$7.52M Sell
172,475
-500
-0.3% -$23.7K 0.58% 44
2020
Q4 		$8.66M Buy
172,975
+18,725
+12% +$794K 0.71% 41
2020
Q3 		$6.49M Buy
+154,250
New +$6.62M 0.63% 41

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Philadelphia Trust Company's RPRX Position: Q3 2023 in Review

Philadelphia Trust Company sold out of Royalty Pharma (RPRX) in Q3 2023, closing a stake of 58,095 shares — an estimated $1.79M sold.

Philadelphia Trust Company first reported a position in RPRX in Q3 2020 and held it in 12 quarters. The position peaked at $9.73M in Q2 2022. 313 funds tracked by Wall St. Rank hold RPRX as of Q3 2023.

  • Philadelphia Trust Company reported no remaining Royalty Pharma position as of Q3 2023 after selling out during the quarter.
  • Philadelphia Trust Company sold 58,095 Royalty Pharma shares in Q3 2023, an estimated $1.79M.
  • Philadelphia Trust Company first reported a position in Royalty Pharma in Q3 2020 and held it in 12 quarters.
  • Philadelphia Trust Company's Royalty Pharma position peaked at $9.73M in Q2 2022.
  • 313 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2023.

Based on Philadelphia Trust Company's 13F filing for Q3 2023, filed 9 Nov 2023.